# CORDIO Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cordio-medical

- Industry: Healthcare IT
- Headquarters: Or Yehuda, Israel
- Website: www.cordio-med.com
- Total disclosed funding: $19M
- Latest round: Series A (Apr 16, 2026)
- Investors on record: 2

## About

In 2013, the company was founded with its business focuses on health tech. In 2021, the company's flagship product HearO was massively covered by Israel media, with a medical study came out in associate with HearO. The study collected 1,484 recordings from the patients and the app successfully identify wet versus dry cases 94% of the time. In 2022, HearO system went to a clinical trial. As of 2022, HeartO has become one of the largest CHF voice-biomarker databases in healthcare.

The company runs a health monitoring app as its flagship product -- HearO™, which can record patients voice via smart phone, and sense fluid accumulation in patients' lungs related to CHF (Congestive Heart Failure) and alert prior to hospitalization. Once the risk is identified, HCPs will be notified and measures can be taken in real time.

## Funding rounds

- Series A, Apr 16, 2026, $0.6M — Peregrine Ventures
- Series A, Oct 1, 2025 — Peregrine Ventures
- Series C, Dec 31, 2024 — Peregrine Ventures
- Series A, Mar 31, 2024 — Peregrine Ventures
- Series A, Jun 27, 2022, $18M — Peregrine Ventures, Ceros Financial Services

## Investors

- Peregrine Ventures (https://capitalatlas.ai/funds/peregrine-ventures) — Series A, Series C
- Ceros Financial Services — Series A